MARKET

TORC

TORC

resTORbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.571
+0.051
+3.32%
Opening 10:26 02/24 EST
OPEN
1.460
PREV CLOSE
1.520
HIGH
1.620
LOW
1.430
VOLUME
754.68K
TURNOVER
--
52 WEEK HIGH
11.96
52 WEEK LOW
0.9400
MARKET CAP
44.05M
P/E (TTM)
-0.8846
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TORC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TORC stock price target is 1.750 with a high estimate of 2.000 and a low estimate of 1.000.

EPS

TORC News

More
  • resTORbio to Present at the 9th Annual Leerink Partners Global Healthcare Conference
  • GlobeNewswire · 4d ago
  • ResTORbio up 12% on encouraging data on lead drug
  • seekingalpha · 4d ago
  • resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinsons Disease and Provides Corporate Update
  • GlobeNewswire · 5d ago
  • Here is What Hedge Funds Think About resTORbio, Inc. (TORC)
  • Insider Monkey · 12/22/2019 23:10

Industry

Pharmaceuticals
-2.11%
Pharmaceuticals & Medical Research
-2.07%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About TORC

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1). Its initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR inhibitors, such as everolimus. Its product pipeline includes the TORC1 program that includes the development of RTB101 for various indications. The indications include respiratory tract infections, heart failure with preserved ejection fraction, autophagy related neurodegenerative diseases and other indications. The Company is developing RTB101 in a Phase II b clinical trial.
More

Webull offers kinds of resTORbio, Inc. stock information, including NASDAQ:TORC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TORC stock news, and many more online research tools to help you make informed decisions.